Is HRT Safe? What 20+ Years of Research Actually Shows
Dr. Karla Loken is a board-certified OB/GYN with over two decades of clinical experience and a distinguished career driving innovation in women's health across the pharmaceutical, diagnostics, and medical device industries. Through her consultancy, Loken & Associates, Dr. Loken provides medical affairs expertise and fractional Chief Medical Officer (CMO) services, helping early-stage companies bridge the gap between scientific innovation and industry application. She serves as Chief Medical Officer to MenoHealth. · 24 min read · Sep 2026
Medically reviewed by Karla F. Loken, DO, FACOOG on September 20, 2026
Is HRT safe? The 2002 WHI scare has been substantially revised by 20+ years of data. Current evidence on safety, timing, and who should consider hormone therapy.
The WHI unnecessarily frightened women and left them suffering with very real symptoms, possibly preventing them from taking a life-changing, even life-prolonging treatment. HRT can have beneficial impacts on bones, brains, and heart — and many common fears around hormone therapy are not supported by the latest scientific evidence.
If you’re asking whether HRT is safe, you’re entering a question that has been answered very differently in 2002 than in 2026. The honest version of the story includes a single July 2002 press release that scared millions of women off hormone therapy, two decades of subsequent reanalysis that walked the initial conclusions back substantially, and a current consensus across major societies that hormone therapy is safe — and meaningfully beneficial — for the right patient at the right time.
This guide walks through what the Women’s Health Initiative actually found, what the 18-year follow-up data later showed, why the original interpretation was wrong for most women, and what the current evidence supports for safety in the women most likely to be considering hormone therapy today. It also covers what’s still uncertain. The picture is more nuanced than either the 2002 panic or the 2026 enthusiasm, and the nuance is what matters for your decision.
Key takeaways
The 2002 Women’s Health Initiative (WHI) report on estrogen-plus-progestin generated headlines about breast cancer and cardiovascular risk that scared a generation of women — and clinicians — off hormone therapy.
Subsequent reanalysis and the 2017 18-year follow-up published in JAMA showed that the absolute risks were small, that they varied substantially by age and time since menopause, and that no excess all-cause mortality was observed in the women studied across nearly two decades.
The timing hypothesis — supported by KEEPS, ELITE, DOPS, and other trials — holds that hormone therapy started under age 60 or within 10 years of menopause has a favorable benefit-risk profile, whereas starting much later carries higher cardiovascular risk.
Current consensus across The Menopause Society 2022 Position Statement, NICE Guideline NG23, and the International Menopause Society endorses hormone therapy as the most effective treatment for vasomotor symptoms and GSM in appropriately selected women.
Hormone therapy is not for everyone — contraindications include estrogen-sensitive cancer history, active venous thromboembolism, active liver disease, and unexplained vaginal bleeding — but for women without contraindications, the safety profile is more favorable than the 2002 narrative suggested.
The short answer
For most women under 60 or within 10 years of their final menstrual period and without specific contraindications, current evidence supports hormone therapy as safe and effective. The Menopause Society 2022 Hormone Therapy Position Statement, NICE Guideline NG23 (updated November 2024), and the International Menopause Society all converge on this framework. Absolute risk increases for breast cancer, stroke, venous thromboembolism, and other outcomes do exist but are small in absolute terms for the typical user and are outweighed by symptom relief, quality-of-life benefits, bone protection, and possible cardiovascular benefit when therapy is started in this window.
The “is HRT safe” question changes substantially when applied to women starting therapy more than 10 years past menopause, or to specific contraindicated groups, or to specific formulations (some routes have lower thrombotic risk than others). Generic answers to the safety question are usually wrong because the right answer depends on which woman, which formulation, and which time window.
The 2002 narrative — that hormone therapy is dangerous and should be avoided — does not match the 2026 evidence. Neither does the opposite narrative that hormone therapy is universally safe and underprescribed. The realistic picture is more useful: hormone therapy is one of the most studied medications in modern medicine, the evidence supports use for the right woman at the right time, and the decision is individual.
The Women’s Health Initiative: what actually happened
The Women’s Health Initiative (WHI) was the largest randomized trial of hormone therapy ever conducted. The hormone therapy components of WHI included two parallel trials: an estrogen-plus-progestin trial (conjugated equine estrogens 0.625 mg + medroxyprogesterone acetate 2.5 mg) in women with a uterus, and an estrogen-alone trial (conjugated equine estrogens 0.625 mg) in women who had had a hysterectomy.
In July 2002, the estrogen-plus-progestin arm was stopped early. Rossouw and colleagues published the principal results in JAMA, reporting increased risks of coronary heart disease, stroke, venous thromboembolism, and invasive breast cancer in the treatment group compared with placebo. The findings were communicated to the public through a press release and immediate media coverage. Within months, hormone therapy prescriptions in the United States dropped by roughly half. Many women stopped HT abruptly. Many clinicians stopped prescribing it. A generation of women navigating menopause symptoms received the message that hormone therapy was dangerous and was no longer a reasonable option.
The data published in that initial 2002 report did show modest excess risks. The absolute risks were small — roughly 8 additional cases of invasive breast cancer per 10,000 women per year on therapy, 7 additional CHD events, 8 additional strokes, 18 additional VTE events — but they were statistically significant, and the framing of the headlines was that hormone therapy caused these outcomes. The estrogen-alone arm of WHI was later stopped early as well, in 2004, with a somewhat different pattern of findings: increased stroke risk but reduced breast cancer risk.
What the 2002 reporting did not adequately convey: the average age of women in WHI was 63, more than a decade past the typical age of menopause. About two-thirds were over 60 at enrollment. Many were starting hormone therapy years to decades after their final menstrual period — a different clinical situation from a woman in her 50s starting hormone therapy for symptoms during the transition. The conclusions were generalized to all women in all circumstances at all ages, regardless of how poorly the WHI population matched the typical clinician decision.
What the 18-year follow-up showed
In 2017, Manson and colleagues published the 18-year follow-up of the WHI hormone therapy trials in JAMA. This is the long-term mortality analysis from the same cohort that produced the 2002 conclusions, and it changed the picture substantially.
The headline finding was that there was no statistically significant difference in all-cause mortality between the women randomized to hormone therapy and those randomized to placebo across nearly two decades of follow-up. No excess deaths. The combined treatment groups had a mortality hazard ratio of 0.99 (95% CI 0.94-1.03) compared with placebo. This is one of the most underreported findings in modern menopause medicine, and it sits at odds with the 2002 narrative that hormone therapy caused harm.
The 2017 analysis also confirmed that risks varied substantially by age at initiation:
Women aged 50-59 at randomization had lower all-cause mortality on hormone therapy than placebo (though the difference didn’t quite reach statistical significance)
Women aged 60-69 had roughly equivalent mortality
HRT is a treatment that is safe, very similar to your body's hormones, and doctor-recommended. There shouldn't be so much stigma around hormone therapy because the benefits outweigh the risks.
Women aged 70-79 had somewhat higher mortality on hormone therapy
This age-stratified pattern is what eventually became known as the timing hypothesis: hormone therapy started near menopause is favorable, while hormone therapy started in much older women carries different and potentially less favorable trade-offs. The implication is that the right time to start HT — if a woman is going to start at all — is during or shortly after the menopause transition, not years or decades later.
The 18-year follow-up also showed that breast cancer findings differed by formulation. Women in the estrogen-plus-progestin arm had a small but statistically significant increased breast cancer risk (consistent with the original findings). Women in the estrogen-alone arm (those who had had a hysterectomy) had a small but statistically significant decreased breast cancer risk. The signal in WHI was not “estrogen causes breast cancer.” It was more specifically about the combination with medroxyprogesterone acetate, the synthetic progestin used in WHI. Subsequent observational data, including the E3N French cohort published in Breast Cancer Research and Treatment, suggested that micronized progesterone (the bioidentical form, available as FDA-approved Prometrium) may have a more favorable breast cancer risk profile than synthetic progestins.
The bone substudy
The bone health findings from WHI deserve their own mention because they’re often left out of the safety conversation. Cauley and colleagues’ 2003 analysis in JAMA reported substantial reductions in clinical fractures — including hip, vertebral, and total fractures — in women on estrogen plus progestin compared with placebo. The hip fracture reduction was particularly notable given the long-term implications of hip fracture for mortality and disability in older women.
The bone benefits of hormone therapy are well-established across multiple trials and observational analyses. For women in the typical age window who have other indications for hormone therapy, bone protection is a substantial co-benefit that often gets overlooked because the conversation gets dominated by cancer and cardiovascular questions. The Menopause Society 2022 position notes that hormone therapy is the most effective treatment for the prevention of menopause-associated bone loss in women in early postmenopause.
The timing hypothesis: KEEPS, ELITE, DOPS
Three randomized trials specifically designed to test hormone therapy in younger postmenopausal women — closer to the typical clinical decision point than the original WHI population — have substantially shaped the modern understanding.
KEEPS (Kronos Early Estrogen Prevention Study). Harman and colleagues’ 2014 publication in Annals of Internal Medicine randomized 727 healthy women aged 42-58 within 3 years of menopause to oral conjugated equine estrogens plus cyclic micronized progesterone, transdermal estradiol plus cyclic micronized progesterone, or placebo for four years. The primary outcome was carotid intimal-medial thickness as a measure of atherosclerosis. Neither hormone regimen accelerated atherosclerosis compared with placebo. Both improved symptoms and bone density. Importantly, the trial showed that hormone therapy started near menopause in healthy women did not produce the cardiovascular signal seen in the older WHI population. The companion KEEPS-Cog cognitive analysis by Gleason and colleagues in PLoS Medicine showed no negative cognitive effects.
ELITE (Early versus Late Intervention Trial with Estradiol). Hodis and colleagues, publishing in the New England Journal of Medicine in 2016, randomized 643 women to oral estradiol plus cyclic vaginal progesterone or placebo, stratified by time since menopause: less than 6 years versus 10+ years. The trial directly tested the timing hypothesis using carotid intimal-medial thickness as the primary endpoint. The results: women who started estradiol within 6 years of menopause had slower progression of carotid atherosclerosis than placebo. Women who started 10+ years out had no difference (some signal toward slightly worse). This is the cleanest randomized test of the timing hypothesis in the literature, and it confirmed that the benefit of starting hormone therapy early is biologically real, not a confounded artifact of healthier women starting earlier.
DOPS (Danish Osteoporosis Prevention Study). Schierbeck and colleagues, publishing in BMJ in 2012, conducted a 16-year randomized trial of hormone therapy in 1,006 women starting therapy soon after menopause. The trial reported significant reductions in a composite cardiovascular endpoint (death, heart failure, myocardial infarction) without increased risks of breast cancer, stroke, or venous thromboembolism in the treatment group. The cardiovascular benefit seen in DOPS is one of the strongest signals supporting the timing hypothesis from a randomized design.
The convergence of KEEPS, ELITE, and DOPS — using different formulations, different endpoints, and different durations — supports the framework that hormone therapy started near menopause has a meaningfully different risk-benefit profile than hormone therapy started later. This is the basis for the modern consensus.
What the current consensus says
The modern consensus has been articulated repeatedly in the major position statements:
The Menopause Society 2022 Hormone Therapy Position Statement. “For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for those at elevated risk for bone loss or fracture.” This is the cornerstone document of contemporary US-based clinical practice.
NICE Guideline NG23 (updated November 2024). Endorses hormone therapy as first-line for bothersome vasomotor symptoms and recommends individualized discussion of benefits and risks. Specifically notes that for most women, the benefits of HT outweigh the risks in the typical clinical decision-making window.
The International Menopause Society 2016 Recommendations. Convergent with The Menopause Society and NICE on the timing framework and the favorable risk-benefit profile in the typical age window.
American College of Obstetricians and Gynecologists. Consistent with the above, endorsing individualized prescribing within the timing framework.
The clinical takeaway: in 2026, the major societies are unanimous that hormone therapy is a reasonable, evidence-supported option for women in the typical window without contraindications. The “should I avoid HT because of the WHI?” framing is not consistent with the current evidence base.
What the risks actually look like in absolute terms
The most useful framing of safety isn’t relative risk in isolation but absolute risk in context. Drawing from WHI data and subsequent analyses, for a typical woman in her 50s starting standard-dose combined hormone therapy:
Breast cancer. Roughly 8 additional cases per 10,000 women per year of use, primarily in users beyond 5 years. The risk attenuates somewhat after stopping. Magnitudes are smaller for estrogen-alone use in women who have had a hysterectomy. Some evidence suggests micronized progesterone may have lower breast cancer risk than synthetic progestins.
Venous thromboembolism (VTE). Roughly 18 additional cases per 10,000 women per year on oral combined therapy. Transdermal estradiol — the patch, gel, or spray — has substantially lower thrombotic risk than oral preparations and is preferred in women with higher baseline VTE risk. For women without specific risk factors, the absolute risk on transdermal HT is small.
Stroke. Modest increase in absolute risk on oral therapy, again with lower risk on transdermal formulations. The increase is most clinically meaningful in older women starting therapy late.
Coronary heart disease. The original WHI signal of increased CHD has not held up well in women starting hormone therapy near menopause. KEEPS, ELITE, and DOPS data suggest neutral-to-favorable cardiovascular effects in this population. The CHD risk associated with later initiation in older women is more substantial.
Endometrial cancer. Unopposed estrogen in women with a uterus increases endometrial cancer risk substantially. This is why progestogen is added to estrogen for women with a uterus. With appropriate progestogen, endometrial cancer risk is not increased.
Mortality. No significant difference across the 18-year WHI follow-up, with possible benefit in women aged 50-59 at initiation.
Cognition. The KEEPS-Cog data showed no cognitive harm from hormone therapy started near menopause. The WHIMS substudy of women starting HT after age 65 did show increased dementia risk. The age and timing pattern is consistent across the cognitive analyses.
The pattern that emerges across outcomes is that absolute risks are small, are concentrated in older women starting therapy late, and are partially modifiable by formulation choice (transdermal vs oral, micronized progesterone vs synthetic progestin).
Who shouldn’t take HRT
Vaginal hormones should be like giving out blood pressure medication to your patients — evidence-based, effective, and offered proactively. Women over 45 should be offered these therapies and understand how safe and effective they are.
Hormone therapy is not appropriate for everyone. The standard contraindications include:
Personal history of breast cancer or other estrogen-sensitive cancer (with some nuance for low-dose vaginal estrogen — see below)
Active or recent venous thromboembolism
Active or recent stroke
Active or recent coronary heart disease (uncomplicated history is more nuanced)
Active liver disease
Unexplained vaginal bleeding (workup required before HT)
Pregnancy
Relative considerations that warrant more careful evaluation include strong family history of breast cancer, history of certain thrombotic risk factors, controlled but significant cardiovascular disease, gallbladder disease, and migraine with aura (where transdermal formulations are typically preferred over oral).
Low-dose vaginal estrogen sits in a different category from systemic HT. The 2018 Crandall analysis of WHI Observational Study data found no increased risks of stroke, CHD, VTE, or breast cancer in users of vaginal estrogen, and the major societies support its use in most postmenopausal women, including (with appropriate input) many breast cancer survivors. Our pillar on is vaginal estrogen safe covers this in depth.
Routes and formulations matter
A frequent oversight in the “is HRT safe” conversation is treating “HRT” as a single product. It isn’t.
Transdermal estradiol (patch, gel, spray) bypasses first-pass hepatic metabolism and is associated with lower thrombotic risk than oral preparations. For women with elevated VTE risk, transdermal is generally preferred. Most modern menopause prescribing favors transdermal as the default route absent specific reasons to choose oral.
Oral estradiol is also FDA-approved and effective but carries higher VTE risk than transdermal.
Conjugated equine estrogens (CEE) — the Premarin formulation used in WHI — is a mixture of estrogen compounds derived from pregnant mare urine. CEE is FDA-approved and effective, but it’s not bioidentical and is used less often in modern prescribing than estradiol.
Micronized progesterone (Prometrium and generics) is the bioidentical progestogen and is the preferred progestogen in modern prescribing. Suggestive evidence indicates a more favorable breast cancer profile than synthetic progestins.
Medroxyprogesterone acetate (MPA) is the synthetic progestin used in WHI. It’s still in use but is generally not the first choice in modern prescribing for women with a uterus on combined HT.
Vaginal estrogen (cream, tablets, ring) delivers very low local doses with minimal systemic absorption and has the most favorable safety profile of any hormone therapy formulation.
For more on what these options look like in practice, see our pillars on HRT explained and HRT benefits. For the bioidentical vs traditional framing, see bioidentical hormones vs traditional HRT.
How long is too long?
The “lowest effective dose for the shortest reasonable duration” framing has evolved. The 2022 Menopause Society position explicitly states that there are no absolute time limits on hormone therapy, and that the decision to continue or stop should be based on ongoing individual benefit-risk assessment. For women with persistent symptoms or other ongoing indications (bone protection in early postmenopause, for example), continuation beyond the historical “5-year” cutoff is reasonable.
For women with premature ovarian insufficiency (POI) or early menopause, the recommendation is full physiologic hormone replacement continued until at least the average age of natural menopause (around 51). See our pillar on premature menopause and POI.
The decision to stop hormone therapy, when it eventually arrives, is also individual. Some women find that symptoms have resolved and can stop without significant rebound. Others find that symptoms return at similar intensity. There’s no universally correct stopping point.
What this means for you
A practical synthesis:
The 2002 narrative is not the 2026 evidence. If you’ve been told that hormone therapy is dangerous because of WHI, that framing reflects the initial reporting, not the subsequent 18-year follow-up or the timing-hypothesis trials. The major societies have updated their positions accordingly.
The timing matters more than almost anything else. Hormone therapy started under age 60 or within 10 years of menopause has a substantially more favorable risk-benefit profile than hormone therapy started much later. If you’re in the typical clinical decision window, you’re in the population where the evidence is most favorable.
The formulation matters. Transdermal estradiol plus micronized progesterone is the modern default for most women without contraindications. It captures the benefits of bioidentical hormone therapy with lower thrombotic risk than oral preparations.
Absolute risks are small for the typical user. The relative risk language used in headlines often obscures how small the absolute risk increases are. For most women, the symptom relief, sleep restoration, bone protection, and possible cardiovascular benefit outweigh the small absolute risk increases.
Contraindications are real and matter. Breast cancer history, active thrombotic disease, unexplained bleeding, and active liver disease aren’t relative concerns to weigh against benefit — they’re situations where HT is not the right choice. Working with a clinician who knows the contraindication map matters.
Vaginal estrogen is in a different safety category. If GSM is your primary concern, low-dose vaginal estrogen has very favorable safety data even in some women who can’t use systemic HT.
The decision is individual, not generic. “Is HRT safe” is the wrong question. “Is HRT safe and appropriate for me, given my age, time since menopause, symptoms, medical history, family history, contraindications, and goals?” is the right question. The answer in a 53-year-old healthy woman with disruptive hot flashes is different from the answer in a 72-year-old woman starting therapy for the first time.
When to talk to your doctor
Reasonable triggers for a clinical conversation about hormone therapy include:
Bothersome vasomotor symptoms (hot flashes, night sweats) at any severity
Sleep disruption from vasomotor symptoms
GSM (vaginal dryness, painful sex, recurrent UTIs)
Bone health concerns or family history of osteoporosis
Premature ovarian insufficiency or early menopause (before age 45)
Surgical menopause (oophorectomy)
Mood changes during the transition
Wanting to revisit a hormone therapy decision you made earlier based on the 2002 framing
Look for a clinician familiar with the current evidence base and the timing hypothesis. The Menopause Society maintains a practitioner directory of certified menopause practitioners.
If you’re preparing for the conversation, our guide on talking to your doctor about menopause covers how to structure it.
Frequently asked questions
Is HRT safe?
For most women under 60 or within 10 years of menopause and without specific contraindications, current evidence supports hormone therapy as safe and effective for vasomotor symptoms, GSM, and bone protection. The 18-year WHI follow-up showed no excess mortality across nearly two decades. Absolute risk increases for specific outcomes exist but are small in absolute terms in the typical user.
Did the Women’s Health Initiative show HRT is dangerous?
The 2002 WHI report showed small relative increases in some risks (breast cancer, CHD, stroke, VTE) and was widely covered as showing harm. The 2017 follow-up by Manson et al. showed no overall mortality difference across 18 years and demonstrated that risks varied substantially by age and time since menopause. The original interpretation has been substantially revised; the 2022 Menopause Society position represents the current evidence-based view.
What is the timing hypothesis?
The framework that hormone therapy started near menopause (under 60 or within 10 years of FMP) has a meaningfully different risk-benefit profile than hormone therapy started much later. KEEPS, ELITE, and DOPS trials support this — women starting HT near menopause showed neutral-to-favorable cardiovascular outcomes; women starting much later did not.
Does HRT cause breast cancer?
For combined estrogen-plus-progestin therapy, there is a small absolute increase in breast cancer risk with longer use (roughly 8 additional cases per 10,000 women per year), primarily seen beyond 5 years. For estrogen-alone therapy in women who have had a hysterectomy, WHI showed a small decrease in breast cancer risk. Evidence suggests micronized progesterone may have a more favorable risk profile than synthetic progestins like MPA.
Should I worry about blood clots on HRT?
Risk depends on formulation. Oral estrogen carries higher VTE risk than transdermal estradiol because of first-pass hepatic effects. For women without specific thrombotic risk factors, transdermal preparations have low absolute VTE risk. For women with elevated baseline risk, transdermal is preferred. This is a conversation to have with your prescriber.
Is bioidentical hormone therapy safer than traditional HRT?
This depends on what’s meant. FDA-approved bioidentical hormone therapy (estradiol + micronized progesterone) is well-studied and safe in appropriate patients. Compounded bioidentical hormone therapy is not FDA-approved, lacks dose standardization, and is not recommended by major societies when FDA-approved alternatives exist. See our pillar on bioidentical hormones vs traditional HRT for the full picture.
Can I stay on HRT forever?
There’s no absolute time limit in current guidelines. The 2022 Menopause Society position explicitly removes the “shortest duration” framing in favor of ongoing individualized benefit-risk assessment. Some women benefit from many years of therapy; others choose to taper after symptoms resolve. The decision is individual and should be revisited periodically.
What if I’m over 60 or more than 10 years past menopause?
Starting HT for the first time outside the typical window is more nuanced and is not generally first-line. For women already on HT who have aged past the window without complications, continuation is often reasonable. For women starting outside the window, the conversation is more individual and depends on symptom severity, alternative options, and overall risk profile. Specialist input is particularly valuable in these cases.
Sources
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA. 2017;318(10):927-938.
Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA. 2003;290(13):1729-1738.
Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial (KEEPS). Annals of Internal Medicine. 2014;161(4):249-260.
Gleason CE, Dowling NM, Wharton W, et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-Cog. PLoS Medicine. 2015;12(6):e1001833.
Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol (ELITE). New England Journal of Medicine. 2016;374(13):1221-1231.
Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial (DOPS). BMJ. 2012;345:e6409.
Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: WHIMS. JAMA. 2003;289(20):2651-2662.
Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause. 2018;25(1):11-20.
Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Research and Treatment. 2008;107(1):103-111.
The Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
National Institute for Health and Care Excellence. Menopause: identification and management (NG23). Updated November 2024.
Disclaimer
This article is for educational purposes and does not constitute medical advice. Always consult a qualified healthcare provider for guidance on your specific situation. Hormone therapy requires evaluation by a clinician familiar with menopause medicine. Contraindications include estrogen-sensitive cancer history, active or recent venous thromboembolism, active or recent stroke, active or recent coronary heart disease, active liver disease, unexplained vaginal bleeding, and pregnancy, among others. Discussions about hormone therapy in women with prior cancer, thrombotic events, or other significant medical history require input from the appropriate specialty teams. The timing-hypothesis framework summarized in this article reflects current consensus across major societies and may evolve as additional evidence accumulates.
